CTOs on the Move

Octant Bio

www.octant.bio

 
Octant is a well-backed team of experienced scientists and entrepreneurs exploring new frontiers of biology. We are applying next-generation DNA sequencing, gene synthesis, and gene editing to revolutionize drug discovery in a quest for safer, more effective, and cheaper drugs.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Octant Bio raised $30M on 05/20/2020

Similar Companies

AC Immune

AC Immune SA, a global leader in developing precision medicine for neurodegenerative diseases (incl. Alzheimer & Parkinsons) with cutting-edge technology platforms

Adaptive Biotechnologies

Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people`s lives by learning from the wisdom of their adaptive immune systems. Adaptive`s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated.

Liphatech

Liphatech is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Premera

Premera is a Mountlake Terrace, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Onconova

Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs. Onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.